Chicago Capital LLC boosted its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 379,582 shares of the company's stock after acquiring an additional 116,931 shares during the period. Chicago Capital LLC owned 0.73% of PROCEPT BioRobotics worth $30,564,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. State Street Corp raised its position in shares of PROCEPT BioRobotics by 5.9% in the third quarter. State Street Corp now owns 1,179,514 shares of the company's stock valued at $94,503,000 after purchasing an additional 66,175 shares during the period. Geode Capital Management LLC grew its stake in PROCEPT BioRobotics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,106,588 shares of the company's stock valued at $88,678,000 after buying an additional 84,244 shares during the last quarter. Westfield Capital Management Co. LP bought a new position in PROCEPT BioRobotics in the 3rd quarter valued at about $72,563,000. Franklin Resources Inc. lifted its position in PROCEPT BioRobotics by 64.5% during the third quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock worth $64,669,000 after acquiring an additional 347,330 shares during the last quarter. Finally, Perpetual Ltd bought a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth approximately $66,972,000. Institutional investors and hedge funds own 89.46% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on PRCT. Morgan Stanley began coverage on PROCEPT BioRobotics in a research note on Monday, December 2nd. They set an "overweight" rating and a $105.00 target price on the stock. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They set a "hold" rating and a $95.00 target price for the company. Wells Fargo & Company restated an "overweight" rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Finally, Truist Financial reiterated a "buy" rating and issued a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $97.86.
Get Our Latest Research Report on PROCEPT BioRobotics
Insider Buying and Selling at PROCEPT BioRobotics
In other news, CEO Reza Zadno sold 26,420 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60. Following the transaction, the chief executive officer now owns 179,185 shares in the company, valued at approximately $17,529,668.55. This trade represents a 12.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Alaleh Nouri sold 28,092 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the sale, the executive vice president now owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,355 shares of company stock valued at $10,327,788 in the last ninety days. 17.40% of the stock is currently owned by company insiders.
PROCEPT BioRobotics Price Performance
PRCT stock traded down $3.02 during midday trading on Thursday, reaching $70.79. The company had a trading volume of 830,063 shares, compared to its average volume of 883,460. PROCEPT BioRobotics Co. has a 1-year low of $45.20 and a 1-year high of $103.81. The stock has a 50 day moving average price of $82.89 and a 200-day moving average price of $79.49. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The company has a market capitalization of $3.69 billion, a price-to-earnings ratio of -36.30 and a beta of 1.03.
About PROCEPT BioRobotics
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
